White Paper

FPP Insight: High Quality Formulation Development At FKPP

Source: Fresenius Kabi Product Partnering

Click Here To Download:
Fresenius Kabi Newsletter: FPP Insight: High Quality Formulation Development At FKPP

By Fresenius Kabi Product Partnering

Our spotlight in this issue is on APP Pharmaceuticals Inc., the newest member of the Fresenius Kabi group. The acquisition of APP in 2008 has given Fresenius Kabi an entry into the U.S. pharmaceutical market and a leading position in the global I.V. generics industry.

APP Pharmaceuticals develops, manufactures and markets injectable pharmaceuticals, with important products in the oncology, anti-infective, anaesthetic / analgesic and critical care fi elds. The company offers one of the most comprehensive portfolios of products used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a complete range of dosage formulations.

Integrating the APP plants into the Fresenius Kabi global production network means that the group now has a presence with substantial manufacturing expertise and technical capabilities in North America.

Click Here To Download:
Fresenius Kabi Newsletter: FPP Insight: High Quality Formulation Development At FKPP